Download PDF
Semin Thromb Hemost 2012; 38(02): 178-184
DOI: 10.1055/s-0032-1301415
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Determination of Rivaroxaban in Human Plasma Samples

Job Harenberg
1   Department of Clinical Pharmacology, Faculty of Medicine, Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany
,
Sandra Erdle
1   Department of Clinical Pharmacology, Faculty of Medicine, Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany
,
Svetlana Marx
1   Department of Clinical Pharmacology, Faculty of Medicine, Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany
,
Roland Krämer
2   Inorganic Chemistry Institute, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
17 February 2012 (online)

    Permissions and Reprints

Abstract

Rivaroxaban is one of the novel oral direct factor Xa inhibitors, which is effective in preventing thromboembolic complications at fixed doses (i.e., once daily), without the need for dose adjustment according to laboratory monitoring. Nearly 60% of rivaroxaban is cleared from circulation by glomerular filtration, 30% of which is excreted as active drug. Therefore, as renal elimination plays a pivotal role in the metabolism of this drug, impairment of renal function may be important during anticoagulation with rivaroxaban over long periods of time. The assessment of the anticoagulant effect/concentration of rivaroxaban may thus be useful in special patient populations such as in the elderly and eldest, during acute diseases with concurrent dehydration, before surgery, during bleeding or thrombotic episodes, or to verify adherence to therapy. Rivaroxaban prolongs prothrombin time in a dose-dependent, linear fashion. Activated partial thromboplastin time (APTT) is also prolonged, but in an exponential manner. Substantial differences in test results might be generated by different thromboplastin and APTT reagents. One-step prothrombin-induced clotting time assay is sensitive to low concentrations of rivaroxaban. Chromogenic substrate assays specific for factor Xa are also sensitive to rivaroxaban. Several initiatives are currently ongoing to standardize the various methods to determine rivaroxaban in human plasma samples, some of which will be summarized in this article along with the dose-dependent effects of rivaroxaban on relevant coagulation parameters. Therefore, although rivaroxaban prolongs all coagulation assays used to assess the anticoagulant effects of most anticoagulants, the most specific assay cannot be identified at present. Moreover, clinical trials are needed to determine the relationship of assay results with bleeding or thrombotic complications.

Keywords

rivaroxaban - prothrombin time assay - activated partial thromboplastin time - thromboplastin reagent - prothrombinase-induced clotting time assay - chromogenic substrate methods
 

  • References

  • 1 Geerts WH, Bergqvist D, Pineo GF , et al; American College of Chest Physicians. Prevention of venous thromboembolism: evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl) 381S-453S
    CrossrefPubMedGoogle Scholar
  • 2 Singer DE, Albers GW, Dalen JE , et al; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl) 546S-592S
    CrossrefPubMedGoogle Scholar
  • 3 Ansell J, Hirsh J, Hylek E , et al; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl) 160S-198S
    CrossrefPubMedGoogle Scholar
  • 4 Hirsh J, Bauer KA, Donati MB , et al; American College of Chest Physicians. Parenteral anticoagulants: evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl) 141S-159S
    CrossrefPubMedGoogle Scholar
  • 5 Schulman S, Beyth RJ, Kearon J, Levine MN ; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl) 257S-298S
    CrossrefPubMedGoogle Scholar
  • 6 Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost 2011; 37 (3) 252-266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Sobieraj-Teague M, O’Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35 (5) 515-524
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78 (4) 412-421
    CrossrefPubMedGoogle Scholar
  • 9 ROCKET AF Investigator II; Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 10 Lippi G, Franchini M, Targher G. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008; 359 (20) 2175-2176
    PubMedGoogle Scholar
  • 11 Fox KA, Piccini JP, Wojdyla D , et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32 (19) 2387-2394
    CrossrefPubMedGoogle Scholar
  • 12 Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50 (10) 675-686
    CrossrefPubMedGoogle Scholar
  • 13 Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation—regulatory considerations. N Engl J Med 2011; 365 (17) 1557-1559
    CrossrefPubMedGoogle Scholar
  • 14 Granger CB, Alexander JH, McMurray JJ , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 15 Kubitza D, Becka M, Mueck W , et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70 (5) 703-712
    CrossrefPubMedGoogle Scholar
  • 16 Asmis LM, Alberio L, Angelillo-Scherrer A , et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb Res 2011; ; August 11 [Epub ahead of print]
    PubMedGoogle Scholar
  • 17 Samama MM, Contant G, Spiro TE , et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators. Thromb Haemost 2012; 107 in press
    PubMedGoogle Scholar
  • 18 Harenberg J. SSC project report: determination of anticoagulant effects of rivaraoxaban: towards a recommendation for assays. Available at: http://www.isth2011.com/ssc-program.html#ssc-session-14 . Assessed Sept 20, 2011
    PubMedGoogle Scholar
  • 19 Roehrig S, Straub A, Pohlmann J , et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48 (19) 5900-5908
    CrossrefPubMedGoogle Scholar
  • 20 Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 2011; 32 (3) 267-271
    CrossrefPubMedGoogle Scholar
  • 21 Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011; 22: 637-641
    CrossrefPubMedGoogle Scholar
  • 22 Samama MM, Martinoli JL, LeFlem L , et al. Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103 (4) 815-825
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011; 9 (1) 226-228
    PubMedGoogle Scholar
  • 24 Calatzis A, Spannagl M, Gempeler-Messina P , et al. The prothrombinase-induced clotting time, a new technique for the monitoring of anticoagulants. Haemostasis 2000; 30 (suppl 2) 172-174
    CrossrefPubMedGoogle Scholar
  • 25 Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost 2007; 33 (5) 503-507
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008; 123 (2) 396-403
    CrossrefPubMedGoogle Scholar
  • 27 Harenberg J, Giese C, Marx M, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38 (1) 16-22
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Perzborn E, Harwardt M, Samama MM. Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor. ISTH 2009; , abstract PP-MO-185
    PubMedGoogle Scholar
  • 29 Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. Clin Chem Lab Med 2011; 49 (5) 755-757
    CrossrefPubMedGoogle Scholar
  • 30 Favaloro EJ, Lippi G. Coagulation update: what’s new in hemostasis testing?. Thromb Res 2011; 127 (Suppl 2) S13-S16
    PubMedGoogle Scholar
  • 31 http://www.isth.org/default/index.cfm/ssc1/2011-ssc-subcommittee-minutes/2011-control-of-anticoagulation-minutes/
    PubMed
  • 32 Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 2002; 32 (4) 174-179
    CrossrefPubMedGoogle Scholar
  • 33 Gehrie E, Laposata M. Test of the month: The chromogenic antifactor Xa assay. Am J Hematol 2011; ; DOI: 10.1002/ajh. 22222
    PubMedGoogle Scholar
  • 34 Harenberg J, Marx S, Erdle S, Krämer R. Determination of the anticoagulant effects of new oral anticoagulants–an unmet need. Expert Rev Haematol 2012; 5 in press
    PubMedGoogle Scholar